Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 250 of 267 entries
View as:

A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Phase: N/A Priority: Normal
NCT ID: NCT02763319 Org: User:
Start: 11/28/16 End: 06/21/24 Due: 06/21/25

To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

Phase: N/A Priority: Normal
NCT ID: NCT04796922 Org: User:
Start: 12/30/22 End: 08/25/32 Due: 08/25/33

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

Phase: N/A Priority: Normal
NCT ID: NCT06615050 Org: User:
Start: 04/02/25 End: 01/17/31 Due: 01/17/32

A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

Phase: N/A Priority: Normal
NCT ID: NCT03235544 Org: User:
Start: 11/20/17 End: 04/30/24 Due: 04/30/25

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Phase: N/A Priority: Normal
NCT ID: NCT04279847 Org: User:
Start: 02/23/21 End: 12/30/26 Due: 12/30/27

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis

Phase: N/A Priority: Normal
NCT ID: NCT05099445 Org: User:
Start: 12/14/21 End: 02/27/23 Due: 02/27/24

Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population

Phase: N/A Priority: Normal
NCT ID: NCT06259669 Org: User:
Start: 09/13/23 End: 08/01/33 Due: 08/01/34

A Study of Ruxolitinib in Pancreatic Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT02119663 Org: User:
Start: 06/30/14 End: 10/31/16 Due: 10/31/17

Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)

Phase: N/A Priority: Normal
NCT ID: NCT04057573 Org: User:
Start: 10/03/19 End: 10/01/21 Due: 10/01/22

A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream

Phase: N/A Priority: Normal
NCT ID: NCT06213831 Org: User:
Start: 02/27/24 End: 08/20/25 Due: 08/20/26

A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06441318 Org: User:
Start: 07/12/24 End: 09/10/24 Due: 09/10/25

Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs

Phase: N/A Priority: Normal
NCT ID: NCT00300573 Org: User:
Start: 04/30/06 End: 04/30/06 Due: 04/30/07

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02265510 Org: User:
Start: 09/10/14 End: 02/27/19 Due: 02/27/20

A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

Phase: N/A Priority: Normal
NCT ID: NCT05879822 Org: User:
Start: 10/30/23 End: 07/22/26 Due: 07/22/27

Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia

Phase: N/A Priority: Normal
NCT ID: NCT00726232 Org: User:
Start: 08/20/08 End: 08/20/18 Due: 08/20/19

Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection

Phase: N/A Priority: Normal
NCT ID: NCT04355793 Org: User:
Start: - End: - Due: -

A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT01685255 Org: User:
Start: 08/31/12 End: 10/23/14 Due: 10/23/15

A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

Phase: N/A Priority: Normal
NCT ID: NCT02998476 Org: User:
Start: 03/02/17 End: 02/05/21 Due: 02/05/22

Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

Phase: N/A Priority: Normal
NCT ID: NCT01632904 Org: User:
Start: 06/30/12 End: 05/31/16 Due: 05/31/17

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Phase: N/A Priority: Normal
NCT ID: NCT06034002 Org: User:
Start: 12/04/23 End: 10/29/28 Due: 10/29/29

Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab

Phase: N/A Priority: Normal
NCT ID: NCT06465433 Org: User:
Start: 11/08/22 End: 08/29/27 Due: 08/29/28

A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

Phase: N/A Priority: Normal
NCT ID: NCT03085914 Org: User:
Start: 05/02/17 End: 07/13/20 Due: 07/13/21

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT00509899 Org: User:
Start: 06/30/07 End: 02/28/17 Due: 02/28/18

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Phase: N/A Priority: Normal
NCT ID: NCT02393248 Org: User:
Start: 02/27/15 End: 12/17/21 Due: 12/17/22

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

Phase: N/A Priority: Normal
NCT ID: NCT04680052 Org: User:
Start: 04/15/21 End: 08/09/28 Due: 08/09/29